Compare Crispr Therapeutics AG (CRSP) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs MasterCard Inc — how do they compare? Crispr Therapeutics AG trades at $50.6 (market cap $4.97B), while MasterCard Inc trades at $539 (market cap $475.39B). The key difference: MasterCard Inc is far larger — about 95.7× Crispr Therapeutics AG's market cap, and MasterCard Inc pays a 0.65% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MA | |
|---|---|---|
Market Cap | $4.97B | $475.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $598.96 |
52-Week Low | $44.34 | $471.55 |
Enterprise Value | $3.32B | $486.13B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mastercard (MA) trades at $537.70, up 2.08% with strong bullish momentum supported by consistent earnings beats and robust financial performance. The stock shows impressive profitability with 45.88% net margins and 232.56% ROE, though valuation multiples remain elevated. Recent institutional buying activity and overwhelmingly positive analyst sentiment reinforce the bullish case, with a consensus price target of $634.27 representing 18% upside potential.
Mastercard's outlook remains positive with strong revenue growth and expanding margins, though premium valuation and emerging payment competition pose risks. The company's aggressive AI investments and global expansion initiatives support continued growth, while stable dividend payments provide shareholder returns. Investors should weigh the stock's quality fundamentals against its rich valuation in current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
